Growth factors: Beyond bone morphogenetic proteins

Journal of Orthopaedic Trauma

Volumn 24, Issue 9, 2010, Pages 543-546

  Nauth, Aaron ^a   Giannoudis, Peter V ^b   Einhorn, Thomas A ^c   Hankenson, Kurt D ^d   Friedlaender, Gary E ^e   Li, Ru ^a   Schemitsch, Emil H ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

bone morphogenetic protein; fracture healing; gene therapy; parathyroid hormone; PDGF; platelet rich plasma; VEGF

Indexed keywords

BONE MORPHOGENETIC PROTEIN; COMPLEMENTARY DNA; PARATHYROID HORMONE; RECOMBINANT PLATELET DERIVED GROWTH FACTOR; VASCULOTROPIN;

BONE INJURY; BONE MINERALIZATION; CLINICAL EXAMINATION; COST BENEFIT ANALYSIS; DIABETES MELLITUS; FRACTURE HEALING; GENE DELIVERY SYSTEM; GENE THERAPY; HUMAN; PERIODONTAL DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; THROMBOCYTE RICH PLASMA; ULCER;

BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 7; BONE MORPHOGENETIC PROTEINS; FRACTURE HEALING; FRACTURES, BONE; GENE THERAPY; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; PARATHYROID HORMONE; RECOMBINANT PROTEINS; WOUND HEALING;

EID: 77956259610     PISSN: 08905339     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOT.0b013e3181ec4833     Document Type: Review

References (21)

1. Govender S, Csimma C, Genant HK, et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am. 2002;84:2123-2134.
2. Friedlaender GE, Perry CR, Cole JD, et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am. 2001;83(Suppl 1):S151-S158.
3. Jones AL, Bucholz RW, Bosse MJ, et al. Recombinant human BMP-2 and allograft compared with autogenous bone graft for reconstruction of diaphyseal tibial fractures with cortical defects. A randomized, controlled trial. J Bone Joint Surg Am. 2006;88:1431-1441.
4. Ristiniemi J, Flinkkila T, Hyvonen P, et al. RhBMP-7 accelerates the healing in distal tibial fractures treated by external fixation. J Bone Joint Surg Br. 2007;89:265-272.
5. Giannoudis PV, Dinopoulos HT. BMPs: options, indications, and effectiveness. J Orthop Trauma. 2010;24(Suppl 1):S9-S16.
6. Nauth A, Ristiniemi J, McKee MD, et al. Bone morphogenetic proteins in open fractures: past, present, and future. Injury. 2009;40(Suppl 3):S27-S31.
7. Aro H, Govender D, Patel A, et al. Recombinant Human Bone Morphogenetic Protein-2 and Reamed Intramedullary Nailing of Tibia Fractures. Proceedings of the 2010 Annual Meeting of the American Academy of Orthopaedic Surgeons. Vol 11. New Orleans, LA; 2010:745.
8. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-1441.
9. Barnes GL, Kakar S, Vora S, et al. Stimulation of fracture-healing with systemic intermittent parathyroid hormone treatment. J Bone Joint Surg Am. 2008;90(Suppl 1):120-127.
10. Kakar S, Einhorn TA, Vora S, et al. Enhanced chondrogenesis and Wnt signaling in PTH-treated fractures. J Bone Miner Res. 2007;22:1903-1912.
11. Bukata S, Kaback L, Reynolds D, et al. 1-34 PTH at Physiologic Doses in Humans Shows Promise as a Helpful Adjuvant in Difficult to Heal Fractures: An Observational Cohort of 145 Patients. Transactions of the 55th Annual Meeting of the Orthopaedic Research Society. Vol 34. Las Vegas, NV; 2009:227.
12. Aspenberg P, Genant HK, Johansson T, et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. July 13, 2009. [Epub ahead of print].
13. Keramaris NC, Calori GM, Nikolaou VS, et al. Fracture vascularity and bone healing: a systematic review of the role of VEGF. Injury. 2008; 39(Suppl 2):S45-S57.
14. Kumar S, Wan C, Ramaswamy G, et al. Mesenchymal stem cells expressing osteogenic and angiogenic factors synergistically enhance bone formation in a mouse model of segmental bone defect. Mol Ther. January 12, 2010. [Epub ahead of print].
15. Li R, Stewart DJ, von Schroeder HP, et al. Effect of cell-based VEGF gene therapy on healing of a segmental bone defect. J Orthop Res. 2009;27: 8-14.
16. Wan C, Gilbert SR, Wang Y, et al. Activation of the hypoxia-inducible factor-1alpha pathway accelerates bone regeneration. Proc Natl Acad Sci\USA. 2008;105:686-691.
17. Shen X, Wan C, Ramaswamy G, et al. Prolyl hydroxylase inhibitors increase neoangiogenesis and callus formation following femur fracture in mice. J Orthop Res. 2009;27:1298-1305.
18. Alsousou J, Thompson M, Hulley P, et al. The biology of platelet-rich plasma and its application in trauma and orthopaedic surgery: a review of the literature. J Bone Joint Surg Br. 2009;91:987-996.
19. Hollinger JO, Hart CE, Hirsch SN, et al. Recombinant human platelet-derived growth factor: biology and clinical applications. J Bone Joint Surg Am. 2008;90(Suppl 1):48-54.
20. Graham S, Leonidou A, Lester M, et al. Investigating the role of PDGF as a potential drug therapy in bone formation and fracture healing. Expert Opin Investig Drugs. 2009;18:1633-1654.
21. Nauth A, Miclau T 3rd, Li R, et al. Gene therapy for fracture healing. J Orthop Trauma. 2010;24(Suppl 1):S17-S24.